



Collaborative Working Project executive summary

Project title Partner organisation/s	A collaborative working agreement between Sanofi and Healthcare Central London to review the community dermatology service and to recommend and implement changes to improve the patient pathway and experience for patients. Healthcare Central London Ltd, Capital House, 25 Chapel Street, London, NW1 5DH Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT
Project rationale	Healthcare Central London (HCL) is a federation of 32 General Practices in Westminster covering 4 Primary Care Networks caring for more than 275,000 registered patients. HCL provide community and primary care services to local residents.
	HCL provides a community dermatology service (CDS) for the constituent GP practices providing a referral management service and single point of access for dermatology. The service has been in operation since 2017. The service receives referrals from HCPs in general practice and provides an advice and guidance service along with diagnosis and treatment plans for referring HCPs to follow. The service reviews referrals and assesses which patients require input from the specialist dermatology outpatient service at the local hospitals. The service receives 200 referrals per month and following review by the CDS only 20% of these referrals are referred onto the secondary care dermatology service. The service is delivered by GPs with Extended Role (GPwERs) in dermatology (formerly known as GPs with Specialist Interest (GPSI's).
	Community Dermatology Service Healthcare Central London
	Healthcare Central London are interested in carrying out a review of the current community dermatology service to understand the current challenges and gaps within the service, to undertake an evaluation of the outcomes of the service and to consider how the service could be improved including potential to strengthen links with the hospital dermatology service to explore the development of improved pathways for specific dermatological conditions within the area. This collaborative working project will support HCL to develop an options appraisal with proposals and recommendations to implement improvements to the





	dermatology service locally that will be fit for purpose both
	now and in the future.
Project period	Q2 2024 – Q1 2025 (9 months)
Project objectives	The collaborative working project will deliver the following
	benefits for Patients, the NHS and Sanofi:
	 Patients: Reduce the time for new patients to receive an appropriate diagnosis and treatment. Reduction in delay for patients for follow-up and review of their treatment thereby having a potential to reduce complications for patients associated with their treatment. Improved equity of access to treatment options as well as a clearer pathway of care with a better experience of the health service. Improvement in patient experience.
	 NHS: Better understanding of the gaps and issues within the community dermatology service and hospital dermatology service production of an options appraisal to improve the service. Completion of a workforce review to deliver improvements in service efficiency. Better identification and more appropriate referrals of suitable patients for specialist hospital review and more timely assessments by the specialist team. Identification of training needs for HCPs in primary care.
	 Sanofi: Improved understanding of the pressure points and priorities associated with a community dermatology service. Improved corporate reputation within Healthcare Central London Imperial College Healthcare NHS Trust and University College London Hospitals NHS Trust. As Sanofi produce medicines within this disease area there may be an increase in the usage of these products in line with national and local guidelines. The project will be delivered by pooling indirect resources by both parties equating to approximately £11,500.





	Central London
Contact details	Healthcare Central London Ltd
	Kirstie Black, Managing Director
	kirstie.black1@nhs.net
	<u>Sanofi</u>
	Fleur Chandler, Head of Market Access
	GB-marketaccess@sanofi.com